Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

被引：24

作者：

Vogel, AM

Lennon, DR

Broadbent, R

Byrnes, CA

Grimwood, K

Mildenhall, L

Richardson, V

Rowley, S

机构：

[1] Univ Auckland, Wellington, New Zealand

[2] Paediat Soc New Zealand, Infect Dis & Immunisat Comm, Wellington, New Zealand

[3] Paediat Soc New Zealand, Fetus & Newborn Comm, Wellington, New Zealand

[4] Paediat Soc New Zealand, Resp Comm, Wellington, New Zealand

来源：

JOURNAL OF PAEDIATRICS AND CHILD HEALTH | 2002年 / 38卷 / 06期

关键词：

consensus; cost effectiveness; palivizumab; preterm; respiratory syncytial virus;

D O I：

10.1046/j.1440-1754.2002.00057.x

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Palivizumab prophylaxis significantly reduces hospitalization for respiratory syncytial virus (RSV) disease in preterm infants. However, palivizumab is very expensive. Data from a New Zealand cost-effectiveness analysis were considered by representatives of the Infectious Diseases and Immunisation, Fetus and Newborn, and Respiratory Committees of the Paediatric Society of New Zealand. Prophylaxis in all high-risk groups was associated with net cost. The consensus panel recommends that the priority for palivizumab be given to babies discharged on home oxygen with chronic lung disease, followed by babies born at 28 weeks or less gestation.

引用

页码：550 / 554

页数：5

共 50 条

[41] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
Robinson, Karen A.
Odelola, Olaide A.
Saldanha, Ian J.
Mckoy, Naomi A.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (02):
[42] Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands
Schepp, Rutger M.
Kaczorowska, Joanna
van Gageldonk, Pieter G. M.
Rouers, Elsbeth D. M.
Sanders, Elisabeth A. M.
Bruijning-Verhagen, Patricia C. J.
Berbers, Guy A. M.
VACCINES, 2023, 11 (12)
[43] Respiratory syncytial virus: Early palivizumab prophylaxis in the NICU
Bonaparte, J
Wu, SY
Pyati, S
Wilks, A
PEDIATRIC RESEARCH, 2002, 51 (04) : 270A - 270A
[44] Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease -: who should receive it?
Sunnegårdh, J
ACTA PAEDIATRICA, 2006, 95 (04) : 388 - 390
[45] Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants
Duppenthaler, A
Gorgievski-Hrisobo, M
Aebi, C
SWISS MEDICAL WEEKLY, 2001, 131 (11-12) : 146 - 151
[46] Palivizumab for the prevention of respiratory syncytial virus infection
Rogovik, Alexander L.
Carleton, Bruce
Solimano, Alfonso
Goldman, Ran
CANADIAN FAMILY PHYSICIAN, 2010, 56 (08) : 769 - 772
[47] Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
Elhalik, M.
El-Atawi, K.
Dash, S. K.
Faquih, A.
Satyan, A. D.
Gourshettiwar, N.
Khan, A.
Varughese, S.
Ramesh, A.
Khamis, E.
CANADIAN RESPIRATORY JOURNAL, 2019, 2019
[48] Respiratory syncytial virus infection in elderly and high-risk adults
Falsey, AR
Hennessey, PA
Formica, MA
Cox, C
Walsh, EE
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17): : 1749 - 1759
[49] Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort
Clark, SJ
Beresford, MW
Subhedar, NV
Shaw, NJ
ARCHIVES OF DISEASE IN CHILDHOOD, 2000, 83 (04) : 313 - 316
[50] Palivizumab prophylaxis for respiratory syncytial virus (RSV) in infants with cystic fibrosis (CF) and respiratory illness hospitalizations
Bjornson, Candice
Chan, Parco
Li, Abby
Paes, Bosco
Lanctot, Krista
Mitchell, Ian
EUROPEAN RESPIRATORY JOURNAL, 2015, 46

← 1 2 3 4 5 →